HUTCHMED (China) (HCM) Jefferies London Healthcare Conference 2024 summary

Company overview and product portfolio

• Headquartered in Hong Kong with integrated R&D, discovery, commercialization, and marketing in China.

• Employs about 2,000 people globally, with a strong clinical development team.

• Three marketed products in China: savolitinib, fruquintinib, and surufatinib, targeting GI oncology, colorectal cancer, neuroendocrine tumors, and MET exon 14 NSCLC.

• Fruquintinib (Fruzaqla) approved in the US for third-line colorectal cancer; EU and Japan approvals expected later this year.

Commercial performance and market expansion

• Fruzaqla achieved over $50 million in US sales in its first quarter, with strong physician uptake.

• The colorectal cancer drug market expanded by 30% year-over-year, with increased treatment duration and market share.

• Partnership with Takeda leverages global commercialization strengths and de-risks US launches.

• Ongoing label expansion for fruquintinib in gastric, endometrial, and renal cancers, with multiple NDAs submitted or expected.

Pipeline and clinical development

• Savolitinib, a MET inhibitor, is in late-stage global trials (SAVANNAH) with AstraZeneca, targeting EGFR-mutant, MET-amplified NSCLC.

• SAVANNAH trial addresses a larger patient population (10-15% in the West, up to 40% in Asia with EGFR mutations).

• First-line and second/third-line label expansions for savolitinib in China are underway, with high response rates and significant PFS improvements.

• SYK inhibitor sovleplenib in ITP showed a 48% overall response rate in phase 3, outperforming existing therapies and demonstrating a strong safety profile.

• Global development for sovleplenib is advancing, with phase 1 trials initiated in the US and other regions.